Ivermectin Should Not Be Recommended to Treat Severe Acute Respiratory Syndrome 2 Infection

To the Editor—Ivermectin is increasingly being used to treat coronavirus disease 2019 (COVID-19) in South America and Africa, despite a lack of robust evidence that such treatment improves clinical outcome. Currently in South Africa, confronted with a third wave of COVID-19 infections, people are even turning to illicit sources to obtain ivermectin [1].

In their meta-analysis of the efficacy of ivermectin to treat COVID-19, published in this journal, Hill et al [2] found that ivermectin reduces clinical recovery time by 1.58 days and mortality from 9.5% to 2.1%. It is the fifth systematic review published on the topic, and 1 of 4 that concludes that there is currently insufficient evidence to recommend ivermectin for the treatment of COVID-19, and that this drug should only be used in clinical trials [3–5]. The only systematic review to conclude that there was strong evidence that ivermectin reduces hospitalization and mortality in COVID-19 patients was first retracted from publication in Frontiers in Pharmacology due to unsubstantiated claims, and later published in the American Journal of Therapeutics [6].

The problem with most ivermectin trials carried is their small sample size (less than 500 participants) and poor quality, which makes it difficult to interpret the results. This is illustrated by the fact that the risk for bias of the different studies is evaluated differently in the different reviews (see Table 1). Since these 5 systematic reviews were published, the results of a new clinical trial have been published [7]. This trial was a well designed, double-blind, and placebo-controlled trial that enrolled 500 persons per arm. Currently, it is the second largest trial that assesses the effect of ivermectin on COVID-19 outcomes. Although it is still underpowered due to a lower percentage of events than expected, this trial did not detect a significant effect of ivermectin on preventing hospitalization nor the need for mechanical ventilatory support [7]. The only other randomized controlled trial considered to be at a low risk for bias in all the systematic reviews also found that ivermectin had no beneficial effect on time-to-recovery (Lopez-Medina et al) (Table 1). Both of these trials were peer-reviewed and published in reputable journals. All of the other trials were either much smaller, not placebo-controlled, or both.

### Table 1. Overview Risk of Bias of Primary Outcome, PCR Outcomes, and Survival Outcomes as Evaluated in Four Systematic Reviews Evaluating the Efficacy of Ivermectin in the Treatment of COVID-19 Infection

| Article                                      | Outcome | Randomized | Placebo | Double-Blind | Sample Size | Peer Review | Underpower | Hill et al [2] | Zein et al [5] | Roman et al [3] | WHO |
|----------------------------------------------|---------|------------|---------|-------------|-------------|-------------|------------|----------------|----------------|-----------------|-----|
| Elgazzar et al [8] | Recovery | Y          | N       | N           | 600         | N           | N          | Low risk       | High risk      | X               | X   |
| Hashim et al [9] | Mortality, recovery | Y          | N       | N           | 140         | N           | Y          | High risk      | High risk      | X               | X   |
| Mahmud et al [10] | Mortality, recovery | Y          | N       | Y           | 363         | Y           | Y          | SC             | High risk      | X               | X   |
| Ahmed et al [11] | Mortality, hospital, recovery | Y          | N       | ?           | 72          | Y           | Y          | Low risk       | X               | High risk      | X   |
| Lopez-Medina et al [12] | Recovery | Y          | Y       | Yα          | 398         | Y           | N          | Low risk       | Low risk       | X               | Low risk |
| Galan et al [13] Pathog Glob Health | Mortality, ICβ | Y          | N       | Y           | 188         | Y           | N          | Low risk       | Low risk       | X               | X   |
| Ravikirti et al [14] | Mortality, IC, recovery | Y          | Y       | Y           | 112         | N           | Y          | SC             | X               | X               | SC |
| Mohan et al [15] | Hospital, IC, recovery | Y          | Y       | Y           | 125         | N           | Y          | SC             | X               | X               | Low risk |
| Okumus et al [16] | Recovery, ICβ | Y          | N       | N           | 66          | Y           | ?          | SC             | High risk      | X               | X   |
| Gonzalez et al [17] | Mortality, hospital | Y          | N       | Y           | 106         | N           | Y          | SC             | X               | X               | Low risk |
| Podder et al [18] | Recovery | Y          | N       | N           | 62          | Y           | Y          | High risk      | X               | High risk      | X   |

Abbreviations: COVID-19, coronavirus disease 2019; IC, intensive care; N, no; PCR, polymerase chain reaction; SC, some concerns; WHO, World Health Organization; Y, yes.

αThe treatment and placebo tasted and smelled different for the first 65 patients.

βOnly severe COVID-19 hospitalized patients included.
and/or not double-blinded. Furthermore, 5 of 11 studies included are unpublished and merely posted on preprint websites (Table 1).

The danger of including these studies is illustrated by the recent retraction of the Elgazzar et al study from the preprint site, which was hosting it after very serious allegations of scientific misconduct [19]. Of all the studies included in the Hill et al review, this study had the biggest effect size. When this study, with a 90% reduction in mortality, is excluded from analysis, no beneficial effect of ivermectin is seen. Thus, we have 2 well conducted, randomized, controlled trials with a low risk of bias that show no effect of ivermectin and a number of other trials either unpublished or at a high risk of bias that show a beneficial effect of ivermectin. In this situation, we consider it inappropriate to use meta-analysis methodology to pool these results. We should limit our evaluation of ivermectin to the evidence derived from high-quality studies. Another high-quality, randomized, controlled trial, the United Kingdom’s Principle outpatient trial, has already enrolled 5000 patients in its ivermectin arm and results are expected soon [20].

In conclusion, based on 4 well conducted systematic reviews and the results of the 2 best-designed clinical trials so far [7], we concur with most international COVID-19 guidelines that the current evidence does not support the use of ivermectin as treatment for COVID-19 infection.

Misinformation about the efficacy of ivermectin in COVID-19 infection should be countered. A paper such as the review by Kory et al [6] is used by influencers and the social media to create confusion and increase the distrust of people in international evidence-based COVID-19 recommendations. What low- and middle-income countries need is more access to oxygen and COVID-19 vaccines, and not ivermectin.

It is now time to conduct trials for a condition for which ivermectin is most useful: onchocerciasis. There is a critical need for clinical trials to evaluate the safety of ivermectin for the treatment of children below the age of 5 years and for pregnant women. Lowering the age to treat children and allowing pregnant women to be treated with ivermectin, together with increasing the frequency of ivermectin distribution, could not only reduce the time to eliminate onchocerciasis but also prevent onchocerciasis-associated morbidities such as onchocerciasis-associated epilepsy [21].

Acknowledgments

Disclaimer. The funder did not influence the writing of this paper in any way.

Financial support. R. C. received funding from VLIR-secretariaat voor universitaire ontwikkelingsaanmerking.

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

A. G. Boven, A. C. Kenyon, and R. Celeboners
1Global Health Institute, University of Antwerp, Antwerp, Belgium;
2Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

References

1. Gewabe L. Health-E News. Desperate times: dealers peddle Ivermectin as COVID-19 continues to rip through South Africa. Available at: https://health-e.org.za/2021/07/11/desperate-times-dealers-peddle-ivermectin-as-covid-19-continues-to-rip-through-south-africa/. Accessed 16 July 2021.
2. Hill A, Garratt A, Levi J, et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Open Forum Infect Dis 2021. doi:10.1093/ofid/ofab558.
3. Roman YM, Burela PA, Pasupuleti V, et al. Ivermectin for the treatment of Coronavirus Disease 2019: a systematic review and meta-analysis of randomized controlled trials. Clin Infect Dis 2021.
4. World Health Organization. Therapeutics and COVID-19: Living Guideline, 31 March 2021. Geneva, Switzerland: World Health Organization; 2021.
5. Zein AFMZ, Sulistiyana CS, Raffaelo WM, Pranata R. Ivermectin and mortality in patients with COVID-19: a systematic review, meta-analysis, and meta-regression of randomized controlled trials. Diabetes Metab Syndr 2021; 15:102186.
6. Kory P, Meduri GU, Varon J, et al. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Am J Ther 2021; 28:e299–318.
7. Vallejos J, Zoni R, Bangher M, et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. BMC Infect Dis 2021; 21:635.
8. Elgazzar A, Hany R, Youssef SA, et al. Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. Res Square. 2020. doi: 10.21203/rs.3.x100956/v3.
9. Hashim HA, Melaulood MF, Rasheed AM, et al. Controlled randomized clinical trial on using ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. medRxiv. 2020. doi: 10.1101/2020.10.26.20219345.
10. Mahmud R, Rahman MM, Alam I, et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. J Int Med Res. 2021; 49(5):3006052110113550.
11. Ahmed S, Karim M, Ross A, et al. A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2020. doi: 10.1016/j.ijid.2020.11.191.
12. López-Medina E, López P, Hurtado IC, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: A Randomized Clinical Trial. JAMA. 2021. doi: 10.1001/jama.2021.3071.
13. Galán LE, Santos NM, Asato MS, et al. Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. Pathog Glob Health. 2021. doi: 10.1080/20477724.2021.1809087.
14. Ravikriti, Roy R, Pattadar C, et al. Ivermectin as a potential treatment for mild to moderate COVID-19 – a double blind randomized placebo-controlled trial. medRxiv. 2021. doi: 10.1101/2021.05.05.21249310.
15. Mohan A, Tiwari P, Suri T, et al. Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial. Research Square 2021.
16. Okumus N. Ivermectin for Severe COVID-19 management. [unpublished] Available at: https://clinicaltrials.gov/ct2/show/NCT04646109. Accessed 13 July 2021.
17. Boltran-Gonzalez JL, Gonzalez-Gomez M, Mendoza-Encio EA, et al. Efficacy and safety of ivermectin and Hydroxychloroquine in patients with severe COVID-19. Available at: https://www.medrxiv.org/content/10.1101/2021.02.12.21252037v1.
18. Poddar S, Chowdhury N, Sina M, Ul Haque W. Outcome of ivermectin treated mild to moderate COVID-19 cases: a single centre, open-label, randomized controlled study. IMC J Med Sci 2021; 24(4):1402.
19. Davey M. Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns. The Guardian. Available at: https://www.theguardian.com/science/2021/jul/16/huge-study-supporting-ivermectin-as-covid-treatment-withdrawn-over-ethical-concerns?CMP=Share_iOSApp_Other. Accessed 15 July 2021.
20. PRINCIPLE. Ivermectin to be investigated in adults aged 18+ as a possible treatment for COVID-19 in the PRINCIPLE trial. Available at: https://www.principletrial.org/news/ivermectin-to-be-investigated-as-a-possible-treatment-for-covid-19-in-oxford2019s-principle-trial. Accessed 16 July 2021.
Colebunders R, Siewe Fodjo JN, Hopkins A, et al. From river blindness to river epilepsy: Implications for onchocerciasis elimination programmes. PLoS Negl Trop Dis. 2019;13:e0007407.

Received 19 July 2021; editorial decision 15 August 2021; accepted 1 September 2021.

Correspondence: Annelies G. Boven, BSc, University of Antwerp Drie Eiken Campus, Universiteit Antwerpen Campus Drie Eiken, Steenbergen, Noord-Brabant, Netherlands (annelies.boven@student.uaantwerpen.be).

Open Forum Infectious Diseases® 2021 © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

https://doi.org/10.1093/ofid/ofab456